acetic acid

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-7.985		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.233		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.885	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	0.536	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	93.680	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	96.700	%	High	1
herg	hERG pIC50	2.879	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	1.611	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	4.188	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	84.240	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70	55
kinase-selectivity-class	ACVR2B,AXL,BRAF,CDK9,DYRK1B,EPHB4,GRK2,MAP2K6,MAPK7,PIK3CD,PIK3CG,PRKDC,STK33,TEK,TGFBR1	15
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.056		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	0.050		High	1
mppb	Mouse plasma protein binding (% unbound)	99.990		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.001		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	97.930	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	0.263	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	99.750	%	High	1
rppb	Rat plasma protein binding (% unbound)	99.490	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	805.378	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Joint dislocation	163.17	15.84	99	15322	44483	90568543
Seronegative arthritis	154.51	15.84	71	15350	18163	90594863
Prescribed underdose	129.30	15.84	105	15316	74914	90538112
Joint stiffness	117.45	15.84	101	15320	77941	90535085
Wound infection	101.46	15.84	107	15314	106295	90506731
Walking aid user	97.96	15.84	66	15355	35440	90577586
Retinitis	95.52	15.84	67	15354	38391	90574635
Osteoporosis	95.48	15.84	99	15322	96432	90516594
Upper respiratory tract infection	94.87	15.84	113	15308	128205	90484821
Lupus vulgaris	94.83	15.84	71	15350	44988	90568038
Visual impairment	93.67	15.84	114	15307	132251	90480775
Lupus-like syndrome	85.47	15.84	69	15352	48777	90564249
Laryngitis	85.24	15.84	70	15351	50683	90562343
Psoriasis	79.22	15.84	111	15310	147643	90465383
Road traffic accident	76.62	15.84	93	15328	107533	90505493
Sciatica	76.10	15.84	90	15331	101292	90511734
Type 2 diabetes mellitus	74.38	15.84	128	15293	203116	90409910
Joint range of motion decreased	68.43	15.84	99	15322	135544	90477482
Hypercholesterolaemia	68.29	15.84	85	15336	100807	90512219
Anti-cyclic citrullinated peptide antibody	66.60	15.84	47	15374	27174	90585852
Broncholithiasis	64.33	15.84	14	15407	293	90612733
Lymph node calcification	61.00	15.84	14	15407	376	90612650
Liver function test increased	59.85	15.84	73	15348	84782	90528244
Adjustment disorder with depressed mood	55.71	15.84	58	15363	56695	90556331
Hepatic cirrhosis	55.67	15.84	61	15360	63192	90549834
Foot deformity	53.32	15.84	58	15363	59593	90553433
Hip arthroplasty	52.83	15.84	65	15356	76143	90536883
Dislocation of vertebra	52.80	15.84	56	15365	55912	90557114
Spinal fusion surgery	52.04	15.84	30	15391	12253	90600773
Osteoarthritis	51.36	15.84	107	15314	195623	90417403
Spondylitis	50.59	15.84	31	15390	14147	90598879
Prescribed overdose	50.30	15.84	72	15349	97553	90515473
Disability	49.94	15.84	47	15374	40698	90572328
Lower limb fracture	48.73	15.84	66	15355	84947	90528079
Knee arthroplasty	48.32	15.84	65	15356	83117	90529909
Exostosis	48.07	15.84	52	15369	53082	90559944
Red blood cell sedimentation rate increased	47.16	15.84	64	15357	82531	90530495
Bone erosion	46.42	15.84	51	15370	52970	90560056
Urticaria	46.00	15.84	137	15284	312597	90300429
Pulmonary fibrosis	45.04	15.84	72	15349	107431	90505595
Deep vein thrombosis postoperative	43.70	15.84	57	15364	70752	90542274
Drug ineffective	42.31	15.84	110	15311	1384188	89228838
Swollen joint count increased	41.90	15.84	71	15350	111135	90501891
Grip strength decreased	41.55	15.84	64	15357	92512	90520514
Irritable bowel syndrome	40.62	15.84	101	15320	207347	90405679
Ear infection	39.73	15.84	54	15367	69721	90543305
Bronchial wall thickening	37.52	15.84	14	15407	2117	90610909
Autoimmune disorder	37.20	15.84	55	15366	76689	90536337
Wheezing	36.61	15.84	106	15315	237974	90375052
Amnesia	34.09	15.84	64	15357	108441	90504585
Lichen nitidus	33.77	15.84	7	15414	115	90612911
Injury	33.41	15.84	91	15330	197258	90415768
Mobility decreased	33.26	15.84	106	15315	250628	90362398
Oedema	32.56	15.84	91	15330	200204	90412822
Drug-induced liver injury	31.83	15.84	56	15365	90262	90522764
Muscular weakness	30.79	15.84	91	15330	206575	90406451
Weight decreased	30.71	15.84	137	15284	379773	90233253
Gait inability	30.45	15.84	73	15348	146383	90466643
Tachycardia	30.04	15.84	76	15345	157597	90455429
Wound	29.76	15.84	116	15305	302864	90310162
Weight increased	28.89	15.84	144	15277	417783	90195243
Oedema peripheral	28.87	15.84	103	15318	257812	90355214
Delirium	28.46	15.84	58	15363	104301	90508725
Memory impairment	27.63	15.84	85	15336	197159	90415867
Fibromyalgia	26.26	15.84	86	15335	206183	90406843
Psoriatic arthropathy	25.39	15.84	91	15330	228244	90384782
Hypoaesthesia	25.15	15.84	113	15308	314097	90298929
Rheumatic fever	24.32	15.84	69	15352	153052	90459974
Liver injury	23.42	15.84	73	15348	170494	90442532
Rheumatoid factor positive	22.23	15.84	72	15349	171578	90441448
Acute kidney injury	20.21	15.84	15	15406	320372	90292654
Muscle injury	20.14	15.84	71	15350	176583	90436443
Impaired healing	20.07	15.84	86	15335	234113	90378913
Breast cancer stage III	19.64	15.84	44	15377	84403	90528623
Sexual abuse	18.57	15.84	5	15416	261	90612765
Anaemia	18.10	15.84	20	15401	352782	90260244
Neutropenia	17.78	15.84	8	15413	224896	90388130
Product use issue	17.71	15.84	18	15403	329901	90283125
C-reactive protein increased	17.42	15.84	69	15352	181320	90431706
Pericarditis	17.18	15.84	91	15330	270060	90342966
Helicobacter infection	16.96	15.84	80	15341	226770	90386256
Soft tissue necrosis	16.85	15.84	6	15415	794	90612232
Gait disturbance	16.74	15.84	88	15333	260408	90352618
Asthenia	16.51	15.84	42	15379	533709	90079317
Drug interaction	16.11	15.84	14	15407	276439	90336587
Pain in extremity	15.95	15.84	131	15290	450398	90162628

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Choroiditis	72.42	20.06	17	2744	1358	42617216
Endophthalmitis	61.00	20.06	19	2742	4414	42614160
Visual acuity reduced	47.39	20.06	23	2738	17527	42601047
Intraocular pressure increased	42.83	20.06	16	2745	6417	42612157
Completed suicide	38.86	20.06	39	2722	96426	42522148
Condition aggravated	34.58	20.06	61	2700	260693	42357881
Eye pain	33.41	20.06	18	2743	17012	42601562
Psoriasis	30.03	20.06	25	2736	48579	42569995
Chondritis	24.85	20.06	5	2756	193	42618381
Testicular haemorrhage	23.55	20.06	5	2756	252	42618322
Toxicity to various agents	23.38	20.06	48	2713	229088	42389486
Post inflammatory pigmentation change	20.31	20.06	5	2756	487	42618087

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Broncholithiasis	67.32	14.08	13	10228	279	110578779
Lymph node calcification	61.17	14.08	13	10228	456	110578602
Choroiditis	58.93	14.08	16	10225	1599	110577459
Psoriasis	49.69	14.08	63	10178	139930	110439128
Completed suicide	49.49	14.08	84	10157	242297	110336761
Toxicity to various agents	47.88	14.08	124	10117	480431	110098627
Endophthalmitis	39.78	14.08	18	10223	8169	110570889
Lichen nitidus	36.48	14.08	7	10234	145	110578913
Bronchial wall thickening	36.43	14.08	13	10228	3194	110575864
Soft tissue necrosis	30.68	14.08	9	10232	1189	110577869
Visual acuity reduced	27.01	14.08	23	10218	32150	110546908
Eye pain	27	14.08	28	10213	50071	110528987
Intraocular pressure increased	26.53	14.08	15	10226	10861	110568197
Therapeutic reaction time decreased	23.74	14.08	11	10230	5268	110573790
Road traffic accident	22.92	14.08	38	10203	107360	110471698
Testicular haemorrhage	21.84	14.08	5	10236	248	110578810
Sciatica	21.50	14.08	34	10207	92365	110486693
Seronegative arthritis	18.98	14.08	13	10228	13164	110565894
Sleep disorder due to general medical condition, insomnia type	18.17	14.08	34	10207	105609	110473449
Spinal fusion surgery	18.05	14.08	11	10230	9145	110569913
Fibromyalgia	16.86	14.08	44	10197	170865	110408193
Chondritis	16.49	14.08	4	10237	255	110578803
Pruritus	16.48	14.08	101	10140	581459	109997599
Fractional exhaled nitric oxide increased	16.29	14.08	5	10236	771	110578287
Post inflammatory pigmentation change	16.28	14.08	5	10236	772	110578286
Penile haemorrhage	15.51	14.08	5	10236	903	110578155
Obstructive airways disorder	15.15	14.08	20	10221	46129	110532929
Type 2 diabetes mellitus	14.86	14.08	43	10198	177189	110401869
Groin infection	14.71	14.08	5	10236	1065	110577993
Colitis ulcerative	14.70	14.08	26	10215	77337	110501721

Source	Code	Description
ATC	G01AD02	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Organic acids
ATC	S02AA10	SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives
CHEBI has role	CHEBI:48356	protic solvent
CHEBI has role	CHEBI:49201	anti-ulcer drug
CHEBI has role	CHEBI:64049	food acidity regulator
CHEBI has role	CHEBI:65256	antimicrobial food preservative
CHEBI has role	CHEBI:67079	anti-inflammatory agent
CHEBI has role	CHEBI:73336	vulnerary
CHEBI has role	CHEBI:83056	<em>Daphnia magna</em> metabolite
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D007202	Indicators and Reagents

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

acetic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Disease	Relation	SNOMED_ID	DOID
Otitis externa	indication	3135009
Otalgia	off-label use	16001004
Impacted cerumen	off-label use	18070006
Otitis Externa Eczema	off-label use
Otitis Externa Seborrhea	off-label use
Herpes zoster auricularis	contraindication	21954000	DOID:9210
Perforation of tympanic membrane	contraindication	60442001
Herpes simplex	contraindication	88594005	DOID:8566
Tuberculosis of ear	contraindication	186269001
Viral ear infection	contraindication	312137007
Fungal ear infection	contraindication	312148000
Infective otitis media	contraindication	312218008
Porphyria	contraindication	418470004
Sensation Disturbance of Genitals	contraindication

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	6.19	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		Kd	6.05	CHEMBL
Free fatty acid receptor 2	GPCR	O15552	FFAR2_HUMAN	AGONIST	EC50	4.60	IUPHAR
Free fatty acid receptor 3	GPCR	O14843	FFAR3_HUMAN		EC50	4.92	CHEMBL

ID	Source
4018456	VUID
N0000146780	NUI
D00010	KEGG_DRUG
4017443	VANDF
4018456	VANDF
C0000983	UMLSCUI
CHEBI:15366	CHEBI
ACY	PDB_CHEM_ID
CHEMBL539	ChEMBL_ID
D019342	MESH_DESCRIPTOR_UI
DB03166	DRUGBANK_ID
1058	IUPHAR_LIGAND_ID
Q40Q9N063P	UNII
176	PUBCHEM_CID
168	RXNORM
11539	MMSL
4122	MMSL
822	MMSL
9812	MMSL
d04228	MMSL
002875	NDDF
002917	NDDF
2869004	SNOMEDCT_US
326289007	SNOMEDCT_US
422082008	SNOMEDCT_US
772941001	SNOMEDCT_US
786281009	SNOMEDCT_US

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	0264-2304	IRRIGANT	0.25 g	IRRIGATION	NDA	21 sections
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0656	IRRIGANT	250 mg	IRRIGATION	NDA	14 sections
hydrocortisone and acetic acid	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0849	SOLUTION	20 mg	AURICULAR (OTIC)	ANDA	12 sections
Fem pH	HUMAN PRESCRIPTION DRUG LABEL	2	0813-0799	JELLY	0.01 g	VAGINAL	unapproved drug other	18 sections
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	0990-6143	IRRIGANT	250 mg	IRRIGATION	NDA	12 sections
acetic acid	HUMAN PRESCRIPTION DRUG LABEL	1	21695-222	SOLUTION	20.65 mg	AURICULAR (OTIC)	NDA	11 sections
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6527	SOLUTION	20.65 mg	AURICULAR (OTIC)	ANDA	12 sections
hydrocortisone and acetic acid	HUMAN PRESCRIPTION DRUG LABEL	2	50383-901	SOLUTION	20.75 mg	AURICULAR (OTIC)	NDA	12 sections
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	50436-4600	SOLUTION	20 mg	AURICULAR (OTIC)	ANDA	11 sections
Hydrocortisone and Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	2	51672-3007	SOLUTION	20.80 mg	AURICULAR (OTIC)	ANDA	13 sections
RELEGARD	HUMAN PRESCRIPTION DRUG LABEL	2	51674-0130	GEL	0.90 mg	TOPICAL	unapproved drug other	3 sections
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	52817-816	SOLUTION	20.65 mg	AURICULAR (OTIC)	ANDA	12 sections
acetic acid	HUMAN PRESCRIPTION DRUG LABEL	1	55045-1243	SOLUTION	20.65 mg	AURICULAR (OTIC)	NDA	11 sections
ACETIC ACID	HUMAN PRESCRIPTION DRUG LABEL	1	60432-741	SOLUTION	20 mg	AURICULAR (OTIC)	ANDA	11 sections
ACETIC ACID	HUMAN PRESCRIPTION DRUG LABEL	1	62135-801	SOLUTION	20 mg	AURICULAR (OTIC)	ANDA	11 sections
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	68071-1739	SOLUTION	20.65 mg	AURICULAR (OTIC)	NDA	10 sections
Acetic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2984	SOLUTION	20.65 mg	AURICULAR (OTIC)	ANDA	12 sections
hydrocortisone and acetic acid	HUMAN PRESCRIPTION DRUG LABEL	2	71656-064	SOLUTION	20.75 mg	AURICULAR (OTIC)	NDA authorized generic	12 sections
ICEKING Skin Expert Anti-onychomycosis Gel	HUMAN OTC DRUG LABEL	2	72501-072	GEL	2 g	CUTANEOUS	Export only	7 sections
New CleanFlex	HUMAN OTC DRUG LABEL	1	81463-0002	LIQUID	1.50 g	TOPICAL	unapproved drug other	7 sections
WART REMOVER	HUMAN OTC DRUG LABEL	8	83619-001	LIQUID	1 g	TOPICAL	OTC Monograph Drug	12 sections
NAIL RENEWAL	HUMAN OTC DRUG LABEL	8	83619-003	LIQUID	1 g	TOPICAL	OTC Monograph Drug	12 sections
Fungal Nail Liquid	HUMAN OTC DRUG LABEL	2	84251-001	LIQUID	10 g	TOPICAL	OTC Monograph Drug	12 sections
FUNGAL NAIL REPAIR	HUMAN OTC DRUG LABEL	1	84445-001	LIQUID	17 g	TOPICAL	OTC Monograph Drug	8 sections
SKIN TAG REMOVER	HUMAN OTC DRUG LABEL	3	87191-001	LIQUID	0.01 g	TOPICAL	OTC Monograph Drug	10 sections